Is NYMX or NOBL a better dividend investment in 2026?

NYMX currently yields 1000.50% with a 5% 5-year dividend growth rate. NOBL yields 4.00% with 5% growth. The better choice depends on your goal: NYMX offers higher current income.

What is the dividend yield difference between NYMX and NOBL?

NYMX has a forward dividend yield of 1000.50% ($2.00/share annually). NOBL yields 4.00% ($2.00/share annually). The yield gap is 996.50 percentage points.

Home › Compare › NYMX vs NOBL

NYMX vs NOBL: Dividend Comparison 2026

NYMX yields 1000.50% · NOBL yields 4.00%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 NYMX wins by $18926778.78M in total portfolio value

INVESTMENT

TIME HORIZON10 years

NYMX

● Live price

1000.50%

Share price

$0.20

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$18926778.81M

Annual income

$15,816,909,097,826.86

Full NYMX calculator →

NOBL

● Live price

4.00%

Share price

$50.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$28.0K

Annual income

$899.19

Full NOBL calculator →

Portfolio growth — NYMX vs NOBL

📍 NYMX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	NYMX	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, NYMX + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

NYMX pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NYMX

Annual income on $10K today (after 15% tax)

$85,042.52/yr

After 10yr DRIP, annual income (after tax)

$13,444,372,733,152.83/yr

NOBL

Annual income on $10K today (after 15% tax)

$340.00/yr

After 10yr DRIP, annual income (after tax)

$764.31/yr

At 15% tax rate, NYMX beats the other by $13,444,372,732,388.52/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NYMX + NOBL for your $10,000?

NYMX: 50%NOBL: 50%

100% NOBL50/50100% NYMX

Portfolio after 10yr

$9463389.42M

Annual income

$7,908,454,549,363.03/yr

Blended yield

83.57%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NYMX buys

NOBL buys

No recent congressional trades found for NYMX or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricNYMXNOBL

Forward yield	1000.50% ✓	4.00%
Annual dividend / share	$2.00	$2.00
Payout ratio	50%	50%
1-year div growth	0%	5% ✓
5-year div CAGR	0%	5% ✓
Portfolio after 10y	$18926778.81M ✓	$28.0K
Annual income after 10y	$15,816,909,097,826.86 ✓	$899.19
Total dividends collected	$18689176.71M ✓	$6.4K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: NYMX vs NOBL ($10,000, DRIP)

Year	NYMX Portfolio	NYMX Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$110,750	$100,050.03	$11,120	$420.00	+$99.6K → NYMX
2	$1,154,067	$1,035,564.75	$12,357	$458.31	+$1.14M → NYMX
3	$11,319,965	$10,085,113.06	$13,721	$499.76	+$11.31M → NYMX
4	$104,563,222	$92,450,859.72	$15,227	$544.58	+$104.55M → NYMX
5	$909,989,518	$798,106,870.01	$16,885	$593.02	+$909.97M → NYMX
6	$7,465,033,954	$6,491,345,169.85	$18,713	$645.34	+$7465.02M → NYMX
7	$57,755,143,367	$49,767,557,036.19	$20,724	$701.81	+$57755.12M → NYMX
8	$421,647,934,611	$359,849,931,208.39	$22,938	$762.73	+$421647.91M → NYMX
9	$2,906,420,287,179	$2,455,256,997,145.24	$25,372	$828.41	+$2906420.26M → NYMX
10	$18,926,778,805,108	$15,816,909,097,826.86	$28,047	$899.19	+$18926778.78M → NYMX

NYMX vs NOBL: Complete Analysis 2026

NYMX — Stock

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.

Full NYMX Calculator →

NOBL — ETF

NOBL is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in NOBL shares.

Full NOBL Calculator →

📬

Get this NYMX vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NYMX vs SCHD NYMX vs JEPI NYMX vs O NYMX vs KO NYMX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.